Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics Of a Generic Formulation Of Intravenous Busulfan (BUCELON 60™) In Patients Undergoing Hematopoietic Stem Cell Transplantation

Ezhilpavai Mohanan, M.Sc, Salamun Desire, M.Sc, Sathya Mani, Gopinath Srinivasan, Biju George, MD, Vikram Mathews, MD, Alok Srivastava, MD, Poonkuzhali Balasubramanian, Ph.D

Blood (2013) 122 (21): 3280.

https://doi.org/10.1182/blood.V122.21.3280.3280

Published: 2013

Journal Articles

Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

Poonkuzhali Balasubramanian, Salamun Desire, M.Sc, John C Panetta, PhD, Kavitha M Lakshmi, MSc, Ezhilpavai Mohanan, M.Sc, Auro Viswabandya, Biju George, MD, Vikram Mathews, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2011) 118 (21): 1941.

https://doi.org/10.1182/blood.V118.21.1941.1941

Published: 2011

Journal Articles

Trough Level of First Dose of Busulfan (Cmin1) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (Css1) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Poonkuzhali Balasubramanian, Ph.D, Salamun Desire, M.Sc, Pranavi Sugumaran, M.Sc, Kavitha ML, M.Sc, Aby Abraham, MD, DM, Auro Viswabandya, MD, DM, Biju George, MD, DM, Vikram Mathews, MD, DM, Mammen Chandy, MD, Rajagopal Krishnamoorthy, D.Sc, Alok Srivastava, MD

Blood (2010) 116 (21): 518.

https://doi.org/10.1182/blood.V116.21.518.518

Published: 2010

Journal Articles

Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation.

Poonkuzhali Balasubramanian, Ph.D, John Carl Panetta, Ph.D, Salamun Desire, M.Sc, Shaji R Velayudhan, Ph.D, Vikram Mathews, MD, Biju George, MD, Auro Viswabandya, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2009) 114 (22): 1182.

https://doi.org/10.1182/blood.V114.22.1182.1182

Published: 2009

Journal Articles

Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassaemia Major Undergoing HSCT.

Poonkuzhali Balasubramanian, Ph.D, Salamun Desire, M.Sc, Vikram Mathews, MD, Kavitha M Lakshmi, M.Sc, Shaji R Velayudhan, Ph.D, Biju George, MD, Auro Viswabandya, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2009) 114 (22): 869.

https://doi.org/10.1182/blood.V114.22.869.869

Published: 2009

Journal Articles

Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.

Poonkuzhali Balasubramanian, Ph.D, John Carl Panetta, Ph.D, Salamun Desire, M.Sc, Shaji R Velayudhan, Ph.D, Vikram Mathews, MD, Biju George, MD, Auro Viswabandya, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2009) 114 (22): 3349.

https://doi.org/10.1182/blood.V114.22.3349.3349

Published: 2009

Journal Articles

Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and Cyclophosphamide for High Risk Patients with Thalassemia Major Undergoing Allogeneic Bone Marrow Transplantation Results in High Rejection Rates.

Mammen Chandy, Vikram Mathews, Biju George, Auro Vishwabandya, Salamun Desire, M.L. Kavitha, Alok Srivastava

Blood (2007) 110 (11): 1998.

https://doi.org/10.1182/blood.V110.11.1998.1998

Published: 2007

NARROW

Pharmacokinetics Of a Generic Formulation Of Intravenous Busulfan (BUCELON 60™) In Patients Undergoing Hematopoietic Stem Cell Transplantation

Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

Trough Level of First Dose of Busulfan (Cmin1) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (Css1) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation.

Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassaemia Major Undergoing HSCT.

Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.

Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and Cyclophosphamide for High Risk Patients with Thalassemia Major Undergoing Allogeneic Bone Marrow Transplantation Results in High Rejection Rates.

Email alerts

ASH Publications

American Society of Hematology

Pharmacokinetics Of a Generic Formulation Of Intravenous Busulfan (BUCELON 60™) In Patients Undergoing Hematopoietic Stem Cell Transplantation

Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

Trough Level of First Dose of Busulfan (Cmin1) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (Css1) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation.

Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassaemia Major Undergoing HSCT.

Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.

Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and Cyclophosphamide for High Risk Patients with Thalassemia Major Undergoing Allogeneic Bone Marrow Transplantation Results in High Rejection Rates.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only